Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...

Some patients with breast cancer who took Verzenio plus endocrine therapy two years after initial treatment demonstrated improved efficacy. Two years of Verzenio (abemaciclib) plus endocrine therapy ...

Verzenio, like many medications, carries the potential for side effects, with common ones including abdominal pain, nausea, vomiting, and fatigue. So it’s important to discuss any concerns with a ...

The analysis showed that treatment with Verzenio in combination with fulvestrant met its secondary endpoint of overall survival. The MONARCH 2 study previously demonstrated a statistically significant ...

Verzenio (abemaciclib) was granted FDA approval for certain patients with advanced or metastatic breast cancer. Verzenio (abemaciclib) was granted FDA approval for the use in combination with Faslodex ...

How Does Verzenio Work for Metastatic Breast Cancer? Verzenio is a type of medicine called a kinase inhibitor. Kinases are enzymes in the body that can send and receive signals to help your cells do ...

INDIANAPOLIS, Oct. 13, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), in combination with endocrine therapy ...

“Metastatic breast cancer is relentless,” says a woman with a determined expression, looking straight into the camera. “But I’m relentless too.” “MBC doesn’t take a day off. And neither will I,” ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

How Does Verzenio Work for Early Breast Cancer? Verzenio is a type of medicine called a kinase inhibitor. Kinases are enzymes in the body that can send and receive signals to help your cells do ...